Join us.


Principal Target Assessment Scientist

With over 35 nationalities and a range of backgrounds represented in our Benevolent team, we aim to build an inclusive environment where our people can bring their authentic selves to work, be respected for who they are and the exceptional work they do. We welcome and actively encourage applications from all sections of society and are committed to offering equal employment opportunities regardless of sex, race, religion or belief, ethnic or national origin, marital, domestic or civil partnership status, sexual orientation, gender identity, parental status, disability, age, citizenship, or any other basis. We see our diversity as an asset as we tackle challenging problems that bridge the gap between drug discovery and technology.


The Role

The Early Discovery Chemistry Team supports the validation of our AI-derived target predictions and facilitates their entry into the BAI drug discovery portfolio. Collaborating with teams across the organisation, we support the development of therapeutic strategies, undertake target tractability assessments and target deconvolution experiments, and build state-of-the-art AI-augmented products to improve the process. We are looking for a highly innovative, proactive and collaborative drug discovery scientist to join our multidisciplinary team.

Primary Responsibilities

  • Lead the chemistry activities across multiple therapy areas in Target ID, to deliver validated targets from our AI platform into the BAI discovery portfolio.
  • Undertake target tractability assessments to support discovery portfolio investment decisions. This includes application of structural bioinformatics tools for druggability, modality and selectivity assessments, as well as analysis of the prior art to define the pre-clinical research strategy.
  • Work alongside target identification biologists to define and execute the validation strategy for targets identified from the BAI knowledge-graph. This includes the judicious use of chemogenomic and biologic tools, assessment of biological data, and specific target deconvolution experiments.
  • Regularly present your research and recommendations for target validation and tractability to the drug discovery senior leadership team.
  • Collaborate with biologists, chemoinformaticians and computational chemists, UX/UI designers, software engineers, NLP researchers and ML scientists, to build products to accelerate the drug discovery process.

We are looking for someone with

  • A PhD or equivalent experience in organic chemistry, medicinal chemistry or chemical biology.
  • >5 years experience in applying medicinal chemistry expertise to drug discovery projects.
  • A track record of significant, innovative personal contributions to the progression of drug discovery programmes.
  • A desire to work closely with biologists in the target identification phase of drug discovery.
  • An ability to react quickly to changing priorities and work dynamically across multiple projects simultaneously.
  • Excellent communication skills, with experience of building cross-discipline relationships.
Nice-to haves
  • Experience of working at the interface between biology and chemistry.
  • A working knowledge of chemical biology techniques for target validation.
  • Evidence of critical assessment of drug targets and chemogenomic tools.
  • A working knowledge of patent law with respect to composition of matter patents.
  • Experience of evaluating competitor pipelines and clinical trial results.
  • A working knowledge of molecular visualisation tools.

We share a passion for being part of a mission that matters, and we are always looking for curious and collaborative people who share our values and want to be part of our journey.  If that sounds like a fit for you, hit the apply button and join us.

About us

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

Want to do a little more research before you apply?

Head over to our Glassdoor page to learn about our benefits, culture and to find out what our team thinks about life at Benevolent. You can also find out more about us on LinkedIn and Twitter.

Important Note

Our team will only contact you from the domain If you receive a suspicious contact request, please email Thank you.